Great Point Partners LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Great Point Partners LLC reported 26 stock positions worth $153.8 million. Its top holding was Ionis Pharmaceuticals (IONS) at 12.8% of the portfolio, followed by Rezolute (RZLT, 8.8%) and Amylyx Pharmaceuticals (AMLX, 8.3%). Compared with Q1 2025, it opened 5 new positions, sold out of 10, added to 7 and reduced 9. The biggest buy was Ionis Pharmaceuticals (IONS, shares +100%) and the biggest sale an exit from Viridian Therapeutics (VRDN).
- Most Recent 13F
- Q2 2026
- Location
- Greenwich, CT
- CIK
- 0001281446
- Portfolio Value
- $153.8M (Q2 2025)
- SEC Filing
- 0001172661-25-003478 ↗ filed Aug 14, 2025
Holdings Value
Holdings 26 stocks · $153.8M
| IONS Ionis Pharmaceuticals Inc. | 12.84% | 500,000 | $19.8M | Add +100.0% |
| RZLT Rezolute Inc. | 8.80% | 3,033,462 | $13.5M | Add +264.1% |
| AMLX Amylyx Pharmaceuticals Inc. | 8.34% | 2,000,000 | $12.8M | Add +10.4% |
| LEGN Legend Biotech Corp.-ADR | 8.08% | 350,000 | $12.4M | Add +153.2% |
| ABVX Abivax SA-ADR | 6.42% | 1,291,617 | $9.9M | Reduce -21.1% |
| NGNE Neurogene Inc. | 4.72% | 485,859 | $7.3M | Add +3.2% |
| AKBA Akebia Therapeutics Inc. | 4.70% | 1,985,915 | $7.2M | Reduce -60.1% |
| EOLS Evolus Inc. | 4.31% | 720,118 | $6.6M | Reduce -23.8% |
| ACLX Arcellx Inc. | 4.28% | 100,000 | $6.6M | Add +122.2% |
| XENE Xenon Pharmaceuticals Inc. | 4.07% | 200,000 | $6.3M | Reduce -18.5% |
| AKRO Akero Therapeutics Inc. | 3.60% | 103,848 | $5.5M | New |
| JBIO Jade Biosciences Inc. | 3.23% | 498,054 | $5.0M | New |
| CYTK Cytokinetics Inc. | 3.22% | 150,000 | $5.0M | Reduce -59.5% |
| IMVT Immunovant Inc. | 2.73% | 262,176 | $4.2M | Reduce -30.1% |
| UNCY Unicycive Therapeutics Inc. | 2.47% | 796,558 | $3.8M | Reduce -27.4% |
| KALV Kalvista Pharmaceuticals Inc. | 2.38% | 323,170 | $3.7M | Reduce -68.1% |
| TSHA Taysha Gene Therapies Inc. | 2.25% | 1,500,000 | $3.5M | New |
| DBVT DBV Technologies SA-Spon ADR | 2.23% | 374,679 | $3.4M | New |
| ZURA Zura Bio Ltd. | 2.16% | 3,170,194 | $3.3M | No change |
| UPB Upstream Bio Inc. | 2.14% | 300,000 | $3.3M | No change |
| CNTX Context Therapeutics Inc. | 2.00% | 4,683,711 | $3.1M | No change |
| CNTA Centessa Pharmaceuticals Ltd. | 1.92% | 225,000 | $3.0M | Add +50.3% |
| SRRK Scholar Rock Holding Corp. | 1.42% | 61,607 | $2.2M | New |
| PMN Promis Neurosciences Inc. | 0.83% | 2,645,128 | $1.3M | No change |
| PLRX Pliant Therapeutics Inc. | 0.64% | 850,000 | $986K | No change |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.20% | 29,381 | $312K | Reduce -92.1% |
Portfolio Sells Q1 2025 → Q2 2025
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −5.50 |
| MRUS Merus NV | Sold out | 0.00% | −5.43 |
| CYTK Cytokinetics Inc. | Reduce -59.5% | 3.22% | −4.86 |
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −4.24 |
| DVAX Dynavax Technologies Corp. | Sold out | 0.00% | −4.20 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -68.1% | 2.38% | −3.99 |
| DNTH Dianthus Therapeutics Inc. | Sold out | 0.00% | −2.71 |
| PCVX Vaxcyte Inc. | Sold out | 0.00% | −2.37 |
| AUTL Autolus Therapeutics PLC | Sold out | 0.00% | −2.30 |
| BBOT Bridgebio Oncology Therapeut | Reduce -92.1% | 0.20% | −2.09 |
| EOLS Evolus Inc. | Reduce -23.8% | 4.31% | −1.87 |
| BEAM Beam Therapeutics Inc. | Sold out | 0.00% | −1.86 |
| MREO Mereo Biopharma Group PL-ADR | Sold out | 0.00% | −1.56 |
| VYGR Voyager Therapeutics Inc. | Sold out | 0.00% | −1.15 |
| UNCY Unicycive Therapeutics Inc. | Reduce -27.4% | 2.47% | −0.96 |
| IMVT Immunovant Inc. | Reduce -30.1% | 2.73% | −0.76 |
| AKBA Akebia Therapeutics Inc. | Reduce -60.1% | 4.70% | −0.49 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -18.5% | 4.07% | −0.40 |
| ABVX Abivax SA-ADR | Reduce -21.1% | 6.42% | +0.86 |
Portfolio Buys Q1 2025 → Q2 2025
| IONS Ionis Pharmaceuticals Inc. | Add +100.0% | 12.84% | +8.74 |
| RZLT Rezolute Inc. | Add +264.1% | 8.80% | +7.48 |
| LEGN Legend Biotech Corp.-ADR | Add +153.2% | 8.08% | +5.53 |
| AMLX Amylyx Pharmaceuticals Inc. | Add +10.4% | 8.34% | +4.85 |
| AKRO Akero Therapeutics Inc. | New | 3.60% | +3.60 |
| JBIO Jade Biosciences Inc. | New | 3.23% | +3.23 |
| ACLX Arcellx Inc. | Add +122.2% | 4.28% | +2.68 |
| TSHA Taysha Gene Therapies Inc. | New | 2.25% | +2.25 |
| DBVT DBV Technologies SA-Spon ADR | New | 2.23% | +2.23 |
| NGNE Neurogene Inc. | Add +3.2% | 4.72% | +1.73 |
| SRRK Scholar Rock Holding Corp. | New | 1.42% | +1.42 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +50.3% | 1.92% | +0.75 |
Options Activity Q1 2025 → Q2 2025
| SMMT Summit Therapeutics Inc. | put | Sold out | 250,000 | $4.8Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 37 | $424.4M | VOR, ABVX, VERA, ZURA, ALMS |
| Q1 2026 | 39 | $408.3M | APGE, VOR, ZURA, AMLX, NKTR |
| Q4 2025 | 29 | $308.4M | APGE, AMLX, ZURA, IRON, RAPT |
| Q3 2025 | 28 | $239.5M | AMLX, RZLT, NKTR, ZURA, SLNO |
| Q2 2025 | 26 | $153.8M | IONS, RZLT, AMLX, LEGN, ABVX |
| Q1 2025 | 31 | $184.0M | CYTK, KALV, EOLS, ABVX, VRDN |
| Q4 2024 | 26 | $212.2M | IONS, CYTK, KALV, VRDN, PLRX |
| Q3 2024 | 29 | $331.4M | NGNE, ABVX, PLRX, EOLS, VRDN |
| Q2 2024 | 33 | $522.0M | URGN, NGNE, ABVX, MRUS, PLRX |
| Q1 2024 | 35 | $641.6M | NGNE, ALPN, URGN, ABVX, EOLS |